Clinical Trials About "Fixed versus Weight Based Dosing Strategy Daptomycin Improve" RSS

13:14 EDT 20th March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Fixed versus Weight Based Dosing Strategy Daptomycin Improve" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "Fixed versus Weight Based Dosing Strategy Daptomycin Improve" on BioPortfolio

We have published hundreds of Fixed versus Weight Based Dosing Strategy Daptomycin Improve news stories on BioPortfolio along with dozens of Fixed versus Weight Based Dosing Strategy Daptomycin Improve Clinical Trials and PubMed Articles about Fixed versus Weight Based Dosing Strategy Daptomycin Improve for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fixed versus Weight Based Dosing Strategy Daptomycin Improve Companies in our database. You can also find out about relevant Fixed versus Weight Based Dosing Strategy Daptomycin Improve Drugs and Medications on this site too.

Showing "Fixed versus Weight Based Dosing Strategy Daptomycin Improve" Clinical Trials 1–25 of 40,000+

Extremely Relevant

Comparison of Ideal vs. Actual Weight Base Factor Dosing

This is a randomized, prospective, multicenter study to examine whether or not the current recommended factor dosing strategy - i.e., dosing by actual body weight - in overweight and obese patients with Hemophilia A may deliver excessive clotting factor to achieve the desired result of bleeding prevention and cessation. This study also examines ways to prevent delivering excessive factor by using a patient's ideal body weight as a new dosing strategy compared to the current dos...

The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock

The first objective of this study was to characterize the pharmacokinetics and pharmacodynamics of daptomycin with a daily dose of 12mg/kg in septic shock patient; the second objective is to identify the optimal dosing scheme for daptomycin among patients with septic shock and to enhance therapeutic outcomes.

A Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.

Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil

Evaluation of the bioavailability and safety of one oral preparation containing fixed dose 18 mg ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) or two oral preparations containing fixed dose 18 mg ivermectin (IVM 36 MG TABLETS, LICONSA S.A., Spain) vs. reference dosing (weight based) of reference drug containing 6 mg ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) in fasting conditions. A monocentric, open, randomized, single dose, three-period crosso...

Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China

The primary objective of this study is to characterise the pharmacokinetics and dose proportionality of daptomycin after single and multiple (once daily) 4mg/kg and 6 mg/kg doses of daptomycin in healthy Chinese volunteers.


Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

The aim of this research is to better understand how patient-level factors can be used to predict the appropriate enoxaparin dose to maximize venous thromboembolism (VTE) risk reduction and minimize bleeding.

Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)

Daptomycin is an antibiotic that is affective against many strains of antibiotic resistant microorganisms. This antibiotic would be appropriate for use in the intensive care unit (ICU) considering the severity of illness and high risk for infection within this hospital environment. While in the ICU, patients may develop acute renal failure. Approximately 75% of ICU patients who develop acute renal failure will require some form of renal replacement therapy until their kidney...

Real-world Daptomycin Use in Chinese ICUs

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.

An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants

This is a safety and pharmacokinetic study of single-dose daptomycin in infants > 48 hours and < 120 days of age with suspected systemic infections. The investigators will enroll a total of 24 infants in 4 gestational age/postnatal age cohorts. Interim analyses will be performed after 3 infants are enrolled in each cohort. The investigators anticipate that 6 mg/kg of daptomycin will yield an AUC

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis

multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE

Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of daptomycin relative to comparator in the treatment of complicated skin and skin structure infections in patients with renal impairment.

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

This is a multicenter, randomized, evaluator-blinded, comparator-controlled study. 1:1 randomization daptomycin or comparator, stratified by degree of renal impairment [creatinine clearance(CLcr) 30 - 50 mL/min and

Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis

Pneumococcal meningitis is an infection of the membrane that covers the brain. It is a serious infection which is currently treated with a combination of corticosteroids (dexamethasone) and 3rd generation cephalosporins. Nevertheless, complications associated with meningitis are relatively frequent and severe. Recent animal studies have shown that another antibiotic, daptomycin, can reduce the mortality and long-term effects of pneumococcal meningitis. Daptomycin is widely used...

Daptomycin Concentration in Drainage Fluid and Blood Samples of ICU Patients

10 patients with chronic heart failure receiving daptomycin therapy after implantation of a left ventricular heart assist system. Measurement of daptomycin levels in drainage fluids (mediastinal and pleural drainage systems) and in blood samples.

Hydroxyurea Optimization Through Precision Study

Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with SCA. The primary objective of the study is to evaluate whether a pharmacokinetics-based starting hydroxyurea dose thieves superior fetal hemoglobin response to to standard weight-based initial dosing. Patients will be recruited from the pediatri...

A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

The goals of the study are to evaluate the feasibility of using daptomycin as a prophylactic antimicrobial agent in patients undergoing cardiac surgery, to determine the rates of surgical site infection, and to evaluate the occurrence of adverse events.

Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections

This is a multicenter, randomized (1:1), semi-single blind study comparing the safety and efficacy of HDSD daptomycin (10 mg/kg q24h for 4 days) with that of comparator (vancomycin +/- SSP for 7-14 days) in patients with cSSSI due to Gram-positive bacteria. Patients will be randomized on a 1:1 basis to receive either daptomycin 10 mg/kg i.v. q24h for 4 days or vancomycin 1 g. q12h for up to 14 days.

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

This investigation is a prospective, open-label pharmacokinetic study of daptomycin prophylaxis in patients undergoing coronary artery bypass graft surgery without valvular replacement.

Dose Individualization of Pemetrexed - IMPROVE-II

Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma. Dosing of cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and toxicity. Administration of pemetrexed to patients with a creatinine clearance 45 ml/min) treatment may be improved by individualized dosing based on renal function, resulting in less toxicity. Also,

Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections

Daptomycin is a cyclic lipopeptide that has been proposed as an alternative therapeutic option in patients with prosthetic joint infection caused by Staphylococcus or Enterococcus species in the latest Infectious Diseases Society of America (IDSA) guidelines. The population pharmacokinetics (PK) of daptomycin have been described in various groups of patients in previous publications. However, little information exists on the PK of daptomycin in patients with bone and joint inf...

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

This is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by Staphylococci. These types of bacteria are among the most common types of bacteria causing infections of prosthetic joints.

Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections

This study will evaluate the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections

Safety Study to Evaluate Daptomycin in Non-Infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis

This study is to examine the safety of daptomycin in patients with End Stage Renal Disease.

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

Daptomycin is a new antimicrobial agent which has activity against resistant Gram positive cocci including MRSA. The phase 3 clinical trials for skin and soft tissue infections (SSTI) with Staphylococci and Streptococci have already demonstrated that daptomycin was noninferior to the comparator agent (vancomycin or beta-lactams) (10). Although this clinical trial did not include any patients with clostridial infection, there is in vitro data to support the activity of daptomyci...

Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight

The purpose of this study is to evaluate the effect of dosing iodinated contrast media according to a patient's total body weight vs. lean body weight. Participants will be randomized into 2 groups based on contrast dosing technique, and solid organ enhancement at uniphasic abdominal CT will be measured.

More From BioPortfolio on "Fixed versus Weight Based Dosing Strategy Daptomycin Improve"

Quick Search